{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:31Z","timestamp":1740148231096,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Scientific Research Foundation of Guangdong Province","award":["A2022539"],"award-info":[{"award-number":["A2022539"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03507-3","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T14:01:42Z","timestamp":1716645702000},"page":"3058-3064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-2449","authenticated-orcid":false,"given":"Xusheng","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hainan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changguo","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linbo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"3507_CR1","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.2147\/OTT.S230309","volume":"12","author":"Y Guo","year":"2019","unstructured":"Guo Y, Cao R, Zhang X, Huang L, Sun L, Zhao J, et al. Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer. OncoTargets Ther. 2019;12:10343\u201360.","journal-title":"OncoTargets Ther"},{"key":"3507_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45.","journal-title":"Mol Cancer"},{"key":"3507_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cam4.2706","volume":"9","author":"H Wang","year":"2020","unstructured":"Wang H, Wang Z, Zhang G, Zhang M, Zhang X, Li H, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med. 2020;9:487\u201395.","journal-title":"Cancer Med"},{"key":"3507_CR4","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/ijms17122132","volume":"17","author":"P Tomasini","year":"2016","unstructured":"Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, et al. EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. Int J Mol Sci. 2016;17:2132.","journal-title":"Int J Mol Sci"},{"key":"3507_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","volume":"13","author":"T Patil","year":"2018","unstructured":"Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13:1717\u201326.","journal-title":"J Thorac Oncol"},{"key":"3507_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5:443\u201352.","journal-title":"Lancet Neurol"},{"key":"3507_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103\u201319.","journal-title":"Cancer Treat Rev"},{"key":"3507_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","volume":"53","author":"J Remon","year":"2017","unstructured":"Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev. 2017;53:128\u201337.","journal-title":"Cancer Treat Rev"},{"key":"3507_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/WCO.0000000000000393","volume":"29","author":"E Le Rhun","year":"2016","unstructured":"Le Rhun E, Galanis E. Leptomeningeal metastases of solid cancer. Curr Opin Neurol. 2016;29:797\u2013805.","journal-title":"Curr Opin Neurol"},{"key":"3507_CR10","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016;11:1962\u20139.","journal-title":"J Thorac Oncol"},{"key":"3507_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11523-018-0581-2","volume":"13","author":"K Saboundji","year":"2018","unstructured":"Saboundji K, Auliac JB, P\u00e9rol M, Fran\u00e7ois G, Janicot H, Marcq M, et al. Efficacy of osimertinib in EGFR-MUTATED non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors. Targeted Oncol. 2018;13:501\u20137.","journal-title":"Targeted Oncol"},{"key":"3507_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol. 2018;29:945\u201352.","journal-title":"Ann Oncol"},{"key":"3507_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"3507_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"3507_CR15","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327\u201334.","journal-title":"J Clin Oncol"},{"key":"3507_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","volume":"43","author":"FJ Lagerwaard","year":"1999","unstructured":"Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795\u2013803.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3507_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1556-0864(15)31569-0","volume":"1","author":"AA Shi","year":"2006","unstructured":"Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205\u201310.","journal-title":"J Thorac Oncol"},{"key":"3507_CR18","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1158\/1078-0432.CCR-10-1588","volume":"16","author":"S Heon","year":"2010","unstructured":"Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873\u201382.","journal-title":"Clin Cancer Res"},{"key":"3507_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","volume":"8","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8:185\u201391.","journal-title":"J Thorac Oncol"},{"key":"3507_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","volume":"31","author":"S Park","year":"2020","unstructured":"Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020;31:1397\u2013404.","journal-title":"Ann Oncol"},{"key":"3507_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","volume":"49","author":"WR Wasserstrom","year":"1982","unstructured":"Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759\u201372.","journal-title":"Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03507-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:37:58Z","timestamp":1731587878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03507-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3507"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03507-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was approved by the ethics committee of Guangdong Sanjiu brain hospital and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This was an observational study that used data previously collected and did not impose any form of intervention. A formal consent to release information form was not required from the Ethics Committee of Guangdong Sanjiu brain hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}